Headlines about Intra-Cellular Therapies (NASDAQ:ITCI) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.6934595150975 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- Intra-Cellular Therapies Inc (ITCI) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- Lawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) Stock (americanbankingnews.com)
- Intra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClub (americanbankingnews.com)
- UPDATE – Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference (finance.yahoo.com)
Several brokerages recently issued reports on ITCI. BidaskClub upgraded shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a report on Tuesday, February 13th. Royal Bank of Canada began coverage on shares of Intra-Cellular Therapies in a report on Thursday, February 8th. They issued an “outperform” rating and a $33.00 target price on the stock. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Saturday, January 13th. ValuEngine cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, Canaccord Genuity began coverage on shares of Intra-Cellular Therapies in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. Intra-Cellular Therapies currently has an average rating of “Buy” and an average price target of $26.70.
In other news, CFO Lawrence J. Hineline sold 3,192 shares of Intra-Cellular Therapies stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $15.67, for a total transaction of $50,018.64. Following the transaction, the chief financial officer now owns 68,686 shares in the company, valued at approximately $1,076,309.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard A. Lerner sold 7,000 shares of Intra-Cellular Therapies stock in a transaction on Monday, December 11th. The stock was sold at an average price of $15.09, for a total transaction of $105,630.00. Following the transaction, the director now owns 8,621 shares in the company, valued at approximately $130,090.89. The disclosure for this sale can be found here. Insiders have sold a total of 105,860 shares of company stock worth $1,961,928 in the last quarter. Corporate insiders own 21.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/intra-cellular-therapies-itci-receiving-somewhat-positive-press-coverage-analysis-finds/1895965.html.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.